2238Biol. Pharm. Bull.30(12) 2238—2243 (2007)Vol. 30, No. 12
Population Pharmacokinetics and Proton Pump Inhibitory Effects ofIntravenous Lansoprazole in Healthy Japanese Males
Yuichi SAKURAI,a,bMasashi HIRAYAMA,bMuneaki HASHIMOTO,bTakanori TANAKA,cSetsuo HASEGAWA,dShin IRIE,eKiyoshi ASHIDA,fYuichiro KAYANO,aMasato TAGUCHI,aand Yukiya HASHIMOTO*,a
Graduate School of Pharmaceutical Sciences, University of Toyama; 2630 Sugitani, Toyama 930–0194, Japan: bTakedaPharmaceutical Company Limited; 4–1–1 Dosyo-machi, Chuo-ku, Osaka 540–8645, Japan: cOhsaki Clinic; 5–7–13Kitashinagawa, Shinagawa-ku, Tokyo 141–0001, Japan: dSekino Clinical Pharmacology Clinic; 3–28–3 Ikebukuro,Toshima-ku, Tokyo 171–0014, Japan: eKyushu Clinical Pharmacology Research Clinic; 2–13–16 Jigyo, Chuo-ku, Fukuoka810–0064, Japan: andfSaiseikai Nakatsu Hospital; 2–10–39 Shibata, Kita-ku, Osaka 530–0012, Japan.Received June 20, 2007; accepted September 18, 2007
A total of 56 healthy Japanese males were enrolled in single- or multiple- dose pharmacokinetic trials of in-travenous lansoprazole administration. The population pharmacokinetics of the drug was evaluated using non-linear mixed effects model (NONMEM) software. In addition, the effect of CYP2C19 polymorphism on protonpump inhibition by lansoprazole was investigated using 24-h intragastric pH monitoring in the 32 subjects. Timecourse of serum lansoprazole concentration following intravenous short infusion was well described by a 2-com-partment model. The mean volume of the central and peripheral compartments was 0.110 and 0.201l/kg, respec-tively. The mean inter-compartment clearance was estimated to be 0.0882l/h/kg. The population mean value ofsystemic clearance in the homoEM (CYP2C19*1/*1), heteroEM (CYP2C19*1/*2and *1/*3), and PM(CYP2C19*2/*2, *2/*3, and *3/*3) groups was 0.179, 0.109, and 0.038l/h/kg, respectively. The mean intragastricpH following twice-daily doses of 30mg lansoprazole was approximately 6, 5, and 4 in the PM, heteroEM, andhomoEM groups, respectively. These ndings indicate that large interindividual variability exists in the pharma-cokinetics of intravenously administered lansoprazole, but that twice-daily infusion of a 30mg dose leads to sig-ni cant and sustained proton pump inhibition, even in the homoEM group, despite the short elimination half-lifeof the drug.
Key words
lansoprazole; population pharmacokinetics; healthy Japanese subject; CYP2C19
a
Upper gastrointestinal bleeding is one of the commoncauses of emergency hospital admission in Japan, and it pos-sibly results in life-threatening massive hemorrhage. Endo-scopic clipping of the bleeding vessel is usually effective fortreating gastrointestinal hemorrhage, but rebleeding occurs in15 to 20% of patients.1)Higher intragastric pH promotesplatelet aggregation, and the inhibition of gastric acid secre-tion to maintain neutral pH may stabilize clots and preventrecurrent bleeding.2)Intravenous administration of histamineH2-receptor antagonists has been widely used for the man-agement of gastrointestinal hemorrhage, particularly after en-doscopic clipping. However, gastric acid secretion is notsolely regulated by the histamine H2-receptor, and toleranceto the antisecretory activity of H2-receptor antagonists fre-quently develops during infusion over 72-h periods, leadingto a loss of pH control.1,3)Meta-analyses have also suggestedthat H2-receptor antagonists only have a weak bene cial ef-fect.4)On the other hand, proton-pump inhibitors (PPIs) sup-press gastric acid secretion by speci c inhibition of theH /K ATPase enzyme system located on the secretory sur-face of gastric parietal cells.5—7)High doses of PPIs maintainthe intragastric pH at a nearly neutral level, and inhibit acidproduction more effectively than an infusion of H2-receptorantagonists.3,8)Therefore, high-dose intravenous PPI therapyis theoretically superior to intravenous H2-receptor antagonisttherapy for the prevention of recurrent bleeding. In fact, sev-eral studies have indicated that intravenous administration ofPPIs is effective for the treatment of patients with gastroin-testinal bleeding.1,4,9,10)
It has been reported that PPIs (omeprazole and lansopra-zole) are mainly metabolized by cytochrome P450 (CYP)
To whom correspondence should be addressed.
2C19.11,12)The genetic polymorphisms of CYP2C19 havebeen observed in Asian populations, and three polymor-phic alleles, CYP2C19*1(wild-type), CYP2C19*2, andCYP2C19*3, have been identi ed among Japanese.13)CYP2C19*2causes a splicing defect in exon 5, andCYP2C19*3creates a premature stop codon in exon 4.13)Therefore, these mutations lead to the complete loss of theenzymatic activity of CYP2C19. The allele frequencies ofCYP2C19*2and CYP2C19*3among Japanese are reportedto be 28.7% and 13.2%, respectively.14)It has been reportedthat genetic polymorphisms of CYP2C19 are responsible forthe large interindividual variability in the pharmacokineticsof orally administered PPIs in Japanese populations.15,16)
Recently, a new preparation for intravenous injection oflansoprazole was developed in Japan. In the present study,we evaluated the population pharmacokinetics of intra-venously administered lansoprazole in healthy Japanese sub-jects using a nonlinear mixed effects model (NONMEM)program. We also evaluated the effect of CYP2C19 polymor-phisms on proton pump inhibition by intravenously adminis-tered lansoprazole.
MATERIALS AND METHODS
SubjectsA total of 56 healthy Japanese adult male vol-unteers participated in this study. All of the subjects werecon rmed to be healthy on the basis of their medical history,physical ndings, laboratory studies, and 12-lead electrocar-diogram. The subjects ranged in age from 20 to 34 (mean S.D.: 24.0 4.0) years old, and their weight ( S.D.) was61.8 6.0kg. The subjects were classi ed into three groups
© 2007 Pharmaceutical Society of Japan
e-mail: yukiya@pha.u-toyama.ac.jp
A population-based study of the drug interaction ...update of their clinical use and pharmacokinetics....inhibitory effects of the proton pump-inhibiting ...
Aim To compare acid-inhibitory effects of the ...ux disease (GERD), proton pump inhibitors (PPIs...and the pharmacokinetics and pharmacodynamics (i.e...
inductive/inhibitory effects of efavirenz on CYP2C...proton-pump inhibitors, clopidogrel, voriconazole, ...Pharmacokinetics and safety of etravirine administered...
proton pump inhibitor.7–9 The emergence of ...pharmacokinetics or tissue accessibility.19,20 Heavy...Immunological features and inhibitory effects on ...
proton pump inhibitor.7–9 The emergence of ...pharmacokinetics or tissue accessibility.19,20 Heavy...Immunological features and inhibitory effects on ...
热门文档